Diarrhoea is a major cause of morbidity and mortality in India. An attempt to formulate a vaccine against this deadly disease, which has claimed so many young lives, is worth the expense.
India is set to begin the phase II clinical trials of a new vaccine for a deadly form of diarrhoea that causes thousands of deaths annually in India. This move has been accelerated after phase I clinical trials showed up to 70 percent success among adults, children and infants.
If the phase II trials are materialized, it is likely to yield more conclusive results towards complete protection from the disease.
The rotaviral diarrhoea contributes 40 percent of the dehydrating diarrhoea disease in infants and young children, causing 150,000 deaths annually in India, which proves that the investment is worthy.
The trial concentrated on the safety and immunogenicity of the two vaccines. The results revealed that the 116E based vaccine is safe and provides up to 70 percent protection with single dose in infants, which may increase to complete protection with two to three doses.
The phase II trial of the 116E vaccine is scheduled to be conducted in New Delhi.
Medindia on Diarrhoea: Replacement of fluids and electrolytes (salts and minerals) lost due to diarrhoea is the main aim. Self-treatment includes avoiding dehydration by drinking lots of electrolyte solutions that are available in all pharmacies and are dispensed without a prescription.
More on Medindia: